BEIJING, March 8 (Xinhua) -- NKY Medical Holdings Ltd. (NKY) announced Thursday that it signed an agreement with Illumina on cooperation in clinical gene testing products development and related technology application.
Under the terms of agreement, the two sides will jointly develop an integrated next generation sequencing (NGS) system.
Based on MiniSeq system and relevant sequencing consumables of Illumina, the system will integrate testing components and sequencers of NKY and provide an economical and ready-to-use in vitro diagnostic (IVD) method for hereditary nephropathy testing.
NKY, established in 1987, is the first Chinese domestic company to develop and manufacture PVP and PVM/MA products in China.
Illumina, headquartered in the United States, is a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. (Edited by Tong Wei, tongwei@xinhua.org)
A single purchase
